Cargando…

Promoter choice: Who should drive the CAR in T cells?

Chimeric antigen receptor (CAR) T cell therapy is an effective treatment for B cell malignancies, with emerging potential for the treatment of other hematologic cancers and solid tumors. The strength of the promoter within the CAR cassette will alter CAR-polypeptide levels on the cell surface of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Rad S. M., Ali Hosseini, Poudel, Aarati, Tan, Grace Min Yi, McLellan, Alexander D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380635/
https://www.ncbi.nlm.nih.gov/pubmed/32706785
http://dx.doi.org/10.1371/journal.pone.0232915